Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2144199 | 0.83 | CCR5 (0.47) | KDM4EATMNPSR1TDP1SLC6A2 | |
| SCHEMBL383264 | 0.83 | CCR5 (0.47) | KDM4EATMNPSR1TDP1SLC6A2 | |
| SCHEMBL383265 | 0.83 | CCR5 (0.47) | KDM4EATMNPSR1TDP1SLC6A2 | |
| SCHEMBL20576050 | 0.83 | KDM4E (0.47) | KDM4EATMNPSR1TDP1SLC6A2 | |
| SCHEMBL20697131 | 0.81 | KDM4E (0.45) | KDM4EATMNPSR1TDP1SLC6A2 | |
| SCHEMBL31266701 | 0.81 | KDM4E (0.45) | KDM4EATMNPSR1TDP1SLC6A2 | |
| SCHEMBL17685375 | 0.80 | CCR5 (0.43) | KDM4EATMNPSR1TDP1SLC6A2 | |
| SCHEMBL17685368 | 0.80 | CCR5 (0.43) | KDM4EATMNPSR1TDP1SLC6A2 | |
| SCHEMBL3376962 | 0.80 | YTHDC1 (0.58) | KDM4EATMNPSR1TDP1SLC6A2 | |
| Hydrochloric Acid SCHEMBL9235596 | 0.78 | CCR5 (0.44) | KDM4EATMNPSR1TDP1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078127-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | BOEHRINGER INGELHEIM INT (DE) | 2026-03-19 | — | — | US | disclosed |
| US-12479818-B2 | Treatment of fibrosis with IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2025-11-25 | — | — | US | disclosed |
| US-12398146-B2 | Heterobicyclic amides as inhibitors of CD38 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-08-26 | — | — | US | disclosed |
| EP-3707126-B1 | IRE1 SMALL MOLECULE INHIBITORS | UNIV CORNELL (US) | 2025-05-14 | — | — | EP | disclosed |
| CN-119431323-A | Heterobicyclic amides as CD38 inhibitors | 贝林格尔·英格海姆国际有限公司 | 2025-02-14 | — | — | CN | disclosed |
| US-20240425477-A1 | IRE1 SMALL MOLECULE INHIBITORS | CORNELL UNIVERSITY | 2024-12-26 | — | — | US | disclosed |
| US-20240368167-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-11-07 | — | — | US | disclosed |
| CN-114423753-B | Heterobicyclic amides as CD38 inhibitors | 里邦医疗公司 | 2024-09-17 | — | — | CN | disclosed |
| US-12071424-B2 | IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2024-08-27 | — | — | US | disclosed |
| US-11987584-B2 | Heterobicyclic amides as inhibitors of CD38 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-05-21 | — | — | US | disclosed |
| US-20230271935-A1 | IRE1 SMALL MOLECULE INHIBITORS | CORNELL UNIVERSITY | 2023-08-31 | — | — | US | disclosed |
| US-11634403-B2 | IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2023-04-25 | — | — | US | disclosed |
| EP-3630748-B1 | IRE1 SMALL MOLECULE INHIBITORS | UNIV CORNELL (US) | 2023-04-19 | — | — | EP | disclosed |
| US-11535621-B2 | Heterobicyclic amides as inhibitors of CD38 | RIBON THERAPEUTICS, INC. (US) | 2022-12-27 | — | — | US | disclosed |
| US-20220265656-A1 | COMBINATION THERAPIES WITH IRE1 SMALL MOLECULE INHIBITORS | CORNELL UNIVERSITY | 2022-08-25 | — | — | US | disclosed |
| US-20220251065-A1 | IRE1 SMALL MOLECULE INHIBITORS | CORNELL UNIVERSITY | 2022-08-11 | — | — | US | disclosed |
| US-20220251065-A1 | IRE1 SMALL MOLECULE INHIBITORS | CORNELL UNIVERSITY | 2022-08-11 | — | — | US | disclosed |
| US-20220227730-A1 | TREATMENT OF FIBROSIS WITH IRE1 SMALL MOLECULE INHIBITORS | CORNELL UNIVERSITY | 2022-07-21 | — | — | US | disclosed |
| CN-114423753-A | Heterobicyclic amides as CD38 inhibitors | 里邦医疗公司 | 2022-04-29 | — | — | CN | disclosed |
| US-20210032251-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271935-A1 | IRE1 SMALL MOLECULE INHIBITORS | XBP1, ERN2, ERN1 | KDM4E 1677/4885ATM 1533/4885NPSR1 4669/4885 |
| US-20240368167-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | CD38, PARP12, ENTPD2 | KDM4E 1792/4885ATM 3996/4885NPSR1 2678/4885 |
| US-20220265656-A1 | COMBINATION THERAPIES WITH IRE1 SMALL MOLECULE INHIBITORS | XBP1, DDIT3, ERN2 | KDM4E 2260/4885ATM 1301/4885NPSR1 4347/4885 |
| US-20240425477-A1 | IRE1 SMALL MOLECULE INHIBITORS | XBP1, ERN2, ERN1 | KDM4E 1677/4885ATM 1533/4885NPSR1 4669/4885 |
| US-20210032251-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | CD38, PARP12, ENTPD2 | KDM4E 1792/4885ATM 3996/4885NPSR1 2678/4885 |
| US-12398146-B2 | Heterobicyclic amides as inhibitors of CD38 | CD38, PARP12, ENTPD2 | KDM4E 1792/4885ATM 3996/4885NPSR1 2678/4885 |
| US-11634403-B2 | IRE1 small molecule inhibitors | XBP1, ERN2, ERN1 | KDM4E 1677/4885ATM 1533/4885NPSR1 4669/4885 |
| US-20260078127-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | CD38, CD22, CD79B | KDM4E 3096/4885ATM 4220/4885NPSR1 103/4885 |
| US-20220227730-A1 | TREATMENT OF FIBROSIS WITH IRE1 SMALL MOLECULE INHIBITORS | XBP1, DDIT3, ATF4 | KDM4E 3118/4885ATM 2571/4885NPSR1 4204/4885 |
| US-11535621-B2 | Heterobicyclic amides as inhibitors of CD38 | CD38, PARP12, ENTPD2 | KDM4E 1792/4885ATM 3996/4885NPSR1 2678/4885 |
| US-12071424-B2 | IRE1 small molecule inhibitors | XBP1, ERN2, ERN1 | KDM4E 1677/4885ATM 1533/4885NPSR1 4669/4885 |
| US-20220251065-A1 | IRE1 SMALL MOLECULE INHIBITORS | XBP1, ERN2, ERN1 | KDM4E 1677/4885ATM 1533/4885NPSR1 4669/4885 |
| US-12479818-B2 | Treatment of fibrosis with IRE1 small molecule inhibitors | XBP1, DDIT3, HSP90B1 | KDM4E 3044/4885ATM 2608/4885NPSR1 4272/4885 |
| US-11987584-B2 | Heterobicyclic amides as inhibitors of CD38 | CD38, PARP12, ENTPD2 | KDM4E 1792/4885ATM 3996/4885NPSR1 2678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.